PMID- 33105621
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201127
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 12
IP  - 11
DP  - 2020 Oct 22
TI  - Hypothyroidism is a Predictive Factor for Better Clinical Outcomes in Patients 
      with Advanced Hepatocellular Carcinoma Undergoing Lenvatinib Therapy.
LID - 10.3390/cancers12113078 [doi]
LID - 3078
AB  - Patients with advanced hepatocellular carcinoma (HCC) undergoing molecular 
      targeted therapy often experience non-negligible adverse events (AEs). 
      Paradoxically, certain AEs are reportedly associated with a good prognosis. We 
      aimed to identify factors predictive of treatment duration and overall survival 
      (OS) in patients with HCC undergoing lenvatinib therapy. Forty-six consecutive 
      patients with advanced HCC who received lenvatinib therapy from April 2018 to 
      November 2019 were prospectively followed until November 2019. Treatment efficacy 
      was assessed according to the modified Response Evaluation Criteria in Solid 
      Tumors for 2-3 months after therapy initiation. The disease control rate (DCR) 
      was defined as the percentage of patients with a complete response, partial 
      response, or stable disease. The DCR was 65.2%, with a median survival of 10.2 
      months. Grade 2/3 hypoalbuminemia resulted in shorter treatment duration. Factors 
      predictive of longer OS were a Child-Pugh score of 5 at baseline and the 
      occurrence of Grade 2/3 hypothyroidism. Conversely, Grade 2/3 hypoalbuminemia was 
      associated with a poorer prognosis. An AE of Grade 2/3 hypothyroidism was 
      associated with a better prognosis in patients receiving lenvatinib treatment for 
      advanced HCC. Continuing anticancer therapy with appropriate thyroid hormone 
      replacement may contribute to longer OS.
FAU - Shomura, Masako
AU  - Shomura M
AUID- ORCID: 0000-0002-2721-9921
AD  - Faculty of Nursing, Tokai University School of Medicine, 143 Shimokasuya Isehara 
      City, Kanagawa 2591193, Japan.
FAU - Okabe, Haruka
AU  - Okabe H
AD  - Faculty of Nursing, Tokai University School of Medicine, 143 Shimokasuya Isehara 
      City, Kanagawa 2591193, Japan.
FAU - Sato, Emi
AU  - Sato E
AD  - Faculty of Nursing, Tokai University School of Medicine, 143 Shimokasuya Isehara 
      City, Kanagawa 2591193, Japan.
FAU - Fukai, Kota
AU  - Fukai K
AD  - Department of Preventive Medicine, Tokai University School of Medicine, 143 
      Shimokasuya Isehara City, Kanagawa 2591193, Japan.
FAU - Shiraishi, Koichi
AU  - Shiraishi K
AD  - Division of Gastroenterology, Department of Internal Medicine, Tokai University 
      School of Medicine, 143 Shimokasuya Isehara City, Kanagawa 2591193, Japan.
FAU - Hirose, Shunji
AU  - Hirose S
AD  - Division of Gastroenterology, Department of Internal Medicine, Tokai University 
      School of Medicine, 143 Shimokasuya Isehara City, Kanagawa 2591193, Japan.
FAU - Tsuruya, Kota
AU  - Tsuruya K
AD  - Division of Gastroenterology, Department of Internal Medicine, Tokai University 
      School of Medicine, 143 Shimokasuya Isehara City, Kanagawa 2591193, Japan.
FAU - Arase, Yoshitaka
AU  - Arase Y
AD  - Division of Gastroenterology, Department of Internal Medicine, Tokai University 
      School of Medicine, 143 Shimokasuya Isehara City, Kanagawa 2591193, Japan.
FAU - Anzai, Kazuya
AU  - Anzai K
AD  - Division of Gastroenterology, Department of Internal Medicine, Tokai University 
      School of Medicine, 143 Shimokasuya Isehara City, Kanagawa 2591193, Japan.
FAU - Kagawa, Tatehiro
AU  - Kagawa T
AUID- ORCID: 0000-0002-5959-913X
AD  - Division of Gastroenterology, Department of Internal Medicine, Tokai University 
      School of Medicine, 143 Shimokasuya Isehara City, Kanagawa 2591193, Japan.
LA  - eng
GR  - 17K12265/JSPS KAKENHI Japan Society for the Promotion of Science Grant-in-Aid for 
      Scientific Research (C)/
PT  - Journal Article
DEP - 20201022
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC7690372
OTO - NOTNLM
OT  - adverse events
OT  - hepatocellular carcinoma
OT  - hypothyroidism
OT  - lenvatinib
COIS- The authors declare no conflict of interest. The funders had no role in the 
      design of the study; in the collection, analyses, or interpretation of data; in 
      the writing of the manuscript, or in the decision to publish the results.
EDAT- 2020/10/28 06:00
MHDA- 2020/10/28 06:01
PMCR- 2020/10/22
CRDT- 2020/10/27 01:01
PHST- 2020/10/06 00:00 [received]
PHST- 2020/10/16 00:00 [accepted]
PHST- 2020/10/27 01:01 [entrez]
PHST- 2020/10/28 06:00 [pubmed]
PHST- 2020/10/28 06:01 [medline]
PHST- 2020/10/22 00:00 [pmc-release]
AID - cancers12113078 [pii]
AID - cancers-12-03078 [pii]
AID - 10.3390/cancers12113078 [doi]
PST - epublish
SO  - Cancers (Basel). 2020 Oct 22;12(11):3078. doi: 10.3390/cancers12113078.